Related Experiment Video

Updated: Jun 21, 2026

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
08:57

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Published on: October 5, 2017

Discontinued drugs in 2008: oncology drugs

Robert Williams1

  • 1Cancer Research UK, Drug Development Office, 61 Lincoln's Inn Fields, London WC2A 3PX, UK. Robert.williams@cancer.org.uk

Expert Opinion on Investigational Drugs
|August 12, 2009
PubMed

Insights

Oncology drug development faces high failure rates. This study analyzes oncology drug candidates discontinued in 2008, identifying key reasons for their termination in clinical trials.

Area of Science:

  • Drug development
  • Oncology
  • Clinical trials

Background:

  • High attrition rates of drug candidates pose significant challenges to the pharmaceutical and biotechnology sectors.
  • Understanding reasons for drug discontinuation is crucial for improving future drug development success rates.

Purpose of the Study:

  • To document oncology drug candidates discontinued during clinical development in 2008.
  • To review the primary reasons cited for the termination of these oncology drug development programs.

Main Methods:

  • Data was extracted from the Pharmaprojects database.
  • The search focused on oncology drug candidates that reached Phase I, II, or III clinical trials in 2008.

Main Results:

  • A specific number of oncology drug candidates were discontinued in 2008.
  • Common reasons for discontinuation included lack of efficacy, safety concerns, and strategic decisions.

Conclusions:

  • The findings highlight the critical need for early identification and mitigation of risks in oncology drug development.
  • Analyzing discontinuation trends can inform strategies to enhance the efficiency and success of pharmaceutical research and development.

Related Concept Videos

FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Prescription, Nonprescription and Orphan Drugs01:02

Prescription, Nonprescription and Orphan Drugs

Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...